Palvella expands QTORIN rapamycin development to angiokeratomas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Palvella Therapeutics (PVLA) PT Raised to $90 at Oppenheimer
September 24, 2025 1:17 PM EDTOppenheimer analyst Trevor Allred raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $90.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Palvella hosted a webcast this morning demonstrating the unmet need and high market potential for Qtorin rapamycin in clinically significant angiokeratomas.... More
